Committee hears proposal to require point‑of‑sale rebates for certain drugs; industry warns of higher premiums

Representative Elkins introduced a bill to require pharmacy benefit managers and health plans to apply negotiated rebates at the pharmacy point of sale so patients pay lower out‑of‑pocket costs for covered drugs. He described incentives in the current system that can favor higher list prices (and bigger rebates) over lower priced alternatives and cited press coverage and studies describing cases where identical medicines have dramatically different patient costs.

Supporters said applying rebates at the point of sale would reduce immediate costs for people who need expensive brand and specialty drugs. Representative Elkins argued the current rebate structure creates "perverse incentives" that result in higher out‑of‑pocket costs for patients even when lower‑priced versions exist.

Industry witnesses cautioned that redirecting rebates to point‑of‑sale discounts could raise premiums. Dan Andreesen (Minnesota Council of Health Plans), Michelle Crimmins (Prime Therapeutics), and Michelle Mack (PCMA) said rebates are used to lower premiums and that requiring point‑of‑sale rebates would shift costs and could prompt manufacturers to reduce rebates. PCMA estimated substantial fiscal impacts over a 10‑year horizon if rebates were redirected at point of sale.

Representative Elkins pointed to the Arkansas implementation and a Milliman analysis as precedent and called it a fair trade — asking plans to use rebate revenue to reduce patient cost sharing rather than solely lowering premiums.

Committee members asked about market coverage and where the requirement would apply; staff and sponsors clarified the draft applies to the fully insured commercial market and that state public programs were excluded by amendment. DHS representatives noted potential impacts to the state preferred drug list and that the agency’s Medicaid preferred drug list can (and does) change quarterly.

The committee heard extensive testimony on tradeoffs: immediate patient savings at the pharmacy counter versus the distribution of rebate dollars to reduce premiums for all enrollees. The bill was laid over for possible inclusion in the omnibus bill while members asked for further fiscal analysis.